Bone marrow transplantation is essentially hematopoietic stem cell transplantation (HSCT). With increasing knowlWe have previously demonstrated that syngeneic maredge of the nature of the stem cell, the characterization of row mixed with H-2 haploidentical marrow transplanstem cell regulation, especially the interaction of the hematation could provide not only protection against grafttopoietic cells with the microenvironment of the marrow, versus-host disease (GVHD) but also anti-leukemic it has been applied to an increasingly wide spectrum of (GVL) effects in mice. In the present studies, we report diseases. More than 10 000 transplants are being done clinical observations using autologous marrow mixed every year throughout the world, including allogeneic bone with HLA-haploidentical allogeneic marrow transplanmarrow transplantation (allo-BMT), and autologous bone tation for treatment of patients with malignant blood marrow transplantation (ABMT) or autologous peripheral diseases. Sixteen cases, including 12 with acute leukemia blood stem cell transplantation (ABSCT). 1,2 Interdisciplinand four with advanced malignant lymphoma, were ary research by numerous investigators around the world treated by autologous marrow, which was purged in continues to expand the scientific basis and clinical results vitro by hyperthemia (42.5؇C for 70 min) following incuof marrow transplantation. However, for treatment of bation for 5 days with interleukin 2 (IL-2) in liquid culmalignant blood diseases, particularly leukemia, allo-BMT ture and mixed with HLA haploidentical marrow cells and ABMT have their strong points and weaknesses, from their sibling or parent. Acute GVHD was not respectively. 3,4 The major advantage of allo-BMT is lower observed in any patient after transplantation. Hematolrelapse after grafting, probably due to graft-versus-leukeogical rescue in the clinical setting was demonstrated mia (GVL) effects mediated by alloreactive donor lymphoin all cases but one who died early from hepatic venocytes. Unfortunately, its disadvantage is also obvious. First, occlusive disease (VOD). Five cases who were transit is limited to a select group of patients with an HLAplanted at the time of CR2 or CR3 and in advanced identical sibling as the donor; only about 40% of patients phase of lymphoma, relapsed 4 to 7 months after transwith acute leukemia have histocompatible donors in westplantation. The relapse rate was 31.3%. None of eight ern countries. It will be difficult to find donors in China in patients who received allogeneic BMT within 2 h after the future, because of birth control. Secondly, it is generally ABMT relapsed wth median follow-up of 12 months and limited to patients under the age of 45 to 50 years. Finally, two of them died from procedure-related complications.
Patients and methods
40 mg/ml and cultured in a 175 cm 2 tissue culture flask. Human recombinant IL-2 (Sinochem United Cross Pharm, Beijing, China) was added at the beginning of the culture Patient characteristics at a concentration of 1000 units/ml. 8 All flasks were placed From February 1993 to May 1996 16 patients with maligin a humidified incubator with 5% CO 2 and maintained at nant blood diseases underwent MBMT. Of these, 12 had 37°C for 5 days. Supernatant cells and adherent cells were acute leukemia (ALL five patients, ANLL seven patients), harvested and washed in 4% human serum albumin solfour advanced malignant lymphoma (Hodgkin's lymphoma ution. The sterility of autografts after culture was routinely one patient, non-Hodgkin's lymphoma three patients). The confirmed by cultures for bacteria and fungi. median age at the time of transplantation was 25 years (range 21-49). The clinical characteristics of the patients Conditioning regimen are summarized in Table 1 . At the time of MBMT, six patients were in first complete remission (CR1), eight in
The ablative-dose chemoradiotherapy consisted of vincris-CR2 and two in CR3.
tine (VCR), cytosine arabinoside (Ara-C), lomustine (CCNU) or VP16, mitoxantrone and cyclophosphamide (CP) plus total body irradiation (Hd-VAC(E)MC+TBI) as Informed consent a conditioning regimen in preparation for ABMT. 9 The HdInformed consent for marrow harvesting and MBMT was VAC(E)MC+TBI regimen is shown in Table 2 in detail. In obtained in all patients and donors. lymphoma patients, boost irradiations (total dose 10-12 Gy) were given over the bulky and original tumor areas. in vitro at first, 7 then suspended in the liquid culture system −1 rest of Iscove's medium (Gibco, Paisley, UK) at a concentration 0 Autologous bone marrow reinfusion followed HLA-haploidentical allogeneic marrow transplantation of 1-2 × 10 7 /ml, which was supplemented with 25% autologous serum, penicillin 100 units/ml and gentamicin CCR 6 months+ LC = lymphocyte depleted; NS = nodular sclerosis; Mix = mixed cellularity; HR = high grade including large cell, immunoblastic or lymphoblastic and small noncleaved cell; CCR = continuous CR; m = month; + = still survive; UPN = unique patient number. Table 4 Median recovery after manipulation
Bone marrow cell collection, processing and purging in vitro
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Donor selection
Selection of a donor was based on HLA-A,B,C typing per- pairs. For them, the donor's marrow cells were transplanted after removing the RBC using separation of sedimentation with 0.4% methylcellulose at 4°C.
GM-CFU and CFU-L assay
recombinant interleukin 2. [10] [11] [12] The starting dose was The assay for GM-CFU was performed according to the 100 × 10 4 unit/day for 4 days, 20 × 10 4 unit/day for 1 week. method of Pike and Robinson.
7 One milliliter of 0.3% agar We also used the human recombinant granulocyte colonyin RPMI-1640 medium supplemented with 20% fetal calf stimulating factor (rHG-CSF, Filgrastim; Kirin, Japan), serum (FCS) and 20% human placenta-conditioned medium 3 × 10 6 unit/day, i.v. for 2 or 3 weeks after MBMT. containing 2 × 10 5 MNC was cultured in triplicate samples for 9 days and scored for colonies (Ͼ40 cells). The result used was the mean value of the triplicate reading. The assay Results for CFU-L was based on a modified method described by Buick et al. 7 Briefly, 1 ml of 0.3% agar in Iscove's medium BM treatment supplemented with 20% FCS and 15% phytohemagglutunin
Initially, a median of 1.0 × 10 8 (range 0.6-1.8) MNCs/kg (PHA) leukocyte-conditioned medium containing 2 × 10 5 and 4.04 × 10 4 (range 2.1-6.8) GM-CFU/kg was treated MNC was plated into 35-mm glass dishes and cultured with hyperthermia, and placed in culture and activated by in humidified 5% CO 2 , 95% air at 37°C. All cultures IL-2. Treatment of the marrow resulted in a median MNCs were done in triplicate. After 7 days of incubation, colonies recovery of 55% (range 28.4-80%), and GM-CFU recovery containing more than 20 cells were counted. CFU-L of 36.4% (range 22-67.8%). For the ANLL, the CFU-L were defined by morphological examination of isolated were considerably reduced, with a median recovery of 2.2% individual colonies.
(range 0-4.2%) ( Table 4) .
Mixed transplantation GVHD complications
In the first eight patients, allogeneic bone marrow cells were reinfused 6 h after ABMT (group 1), and the latter Acute GVHD was not observed in any patients (group 1 and 2) after MBMT. However, chronic GVHD (cGVHD) eight patients, 2 h after ABMT (group 2). The mean autologous marrow MNCs and GM-CFU transplanted were occurred in eight patients in group 2, with a median of 25 days (range 21-to 32) post-MBMT. The major manifes-0.54 × 10 8 /kg, and 1.47 × 10 4 /kg, respectively. According to the result in mice, 16 the number of donor's marrow tations were skin lesions including thickened skin, diffuse hyperpigmentation, buccal mucositis, weight loss, chronic MNCs and GM-CFU transplanted were 0.096 × 10 8 /kg and 0.41 × 10 4 /kg, which were approximately a sixth and a liver disorders, failure to thrive, and so on. The characteristics of the cGVHD in the eight cases are shown in fourth of autologous grafting, respectively (Table 3) .
All patients were managed in laminar flow isolation with Table 5 . gut decontamination until their white blood cells (WBC) reached 2 × 10 9 /l. During the period of marrow aplasia, antibiotics, platelet components, and other supportive care were also given. 
Survival Discussion
In terms of overall survival, five of 16 patients relapsed In order to exploit the advantages of allogeneic and autowithin 4 to 7 months after MBMT, a relapse rate of 31.3%. logous hematopoietic stem cell transplantation, and to Four patients died from complications and non-hematologic develop a new effective approach for treating patients with disorders, the actuarial disease-free survival (DFS) was malignant diseases, particularly malignant blood diseases, 44.8% with median follow-up of 12 months. However, in we have attempted to find a potential way of using autologgroup 2, none of them relapsed with median follow-up of ous BMT combined with allogeneic BMT. Several prob-12 months (range 6-19 months). All patients but two, who lems should be understood before it is used in a clinical died from fulminant hepatitis and appendicular perforation setting. First, it should be safe, the recipient immunotolerat 3 and 8 months after MBMT, respectively, are still alive ance to HLA-mismatched hematologic stem cell in DFS. In contrast, five of eight patients in group 1 engraftment could be induced enough to avoid severe relapsed with a median of 4 months, and died within 5-GVHD after mixed BMT. Second, it is important to know 14 months, two died from hepatic veno-occlusive disease which donor should be selected, how many allogeneic stem (HVOD) and encephalopathy at 3 and 7 weeks, respectcells should be mixed, and what is the optimal time for ively. Only one patient is still DFS for more than 40 allogeneic marrow cell transplantation. Finally, it should months.
increase the long-term disease-free survival in patients with Figure 1 shows that overall probability of relapse-free malignant diseases, ie more effective GVL should be survival (RFS) is 50.6%. The probability of RFS is 19% induced by MBMT in some way, such as using cytokines. for group 1 and 100% for group 2 at 14 months.
Based on the recent results of immunotolerance studies in animals, 13,14 some investigators have described a murine model for the development of donor-specific tolerance Engraftment and hematopoietic reconstitution across complete MHL barriers using lethal irradiation folFifteen patients were successfully engrafted after MBMT.
lowed by reconstitution with a mixture of T cell-depleted The mean time for reaching a neutrophil count Ͼ0.5 × 10 9 /l (TCD) syngeneic and TCD allogeneic bone marrow. 15 Such was 27(±7.3) days, and recovery to platelets Ͼ50 × 10 9 /l animals develop stable mixed chimerism and immunocomwas 38 (±18) days. One patient had persistent pancytopenia petence without clinical evidence of GVHD. Recently, we for 8 months after increasing leukocytes and platelets in have studied the graft-versus-leukemia effect of syngeneic the short period following MBMT for cGVHD. One patient marrow mixed with H-2 haploidentical marrow grafting died from HVOD before complete hematologic reconstiand it's tolerance without graft-versus-host disease. 16 By tution could occur. We did not find significant correlations use of spleen enlargement of neonatal mice and mortality between the number of GM-CFU infused and the time to of sublethally irradiated adult mice after the i.p. injection reach a granulocyte count Ͼ0.5 × 10 9 /l or platelet count of mixed spleen cells, the results showed that syngeneic Ͼ50 × 10 9 /l. cells mixed with 1/6 H-2 haploidentical spleen cells significantly reduced GVHD in neonatal mice, and prevented lethal GVHD in sublethally irradiated adult mice. Lethally Chimerism in survivors irradiated 615 (H-2k) mice were given a lethal dose of 615 Mixed chimerism was found in three of six cases, who had leukemic cells along with syngeneic marrow or a mixture different sex donors, by analysis of sex chromosomes. Two of syngeneic plus 1/6 H-2 haploidentical marrow cells and of them have been followed-up for more than 12 months. the anti-leukemic effects of mixed marrow transplantation were demonstrated. This observation may suggest a potential way to reduce relapse and increase the safety of clinical autologous marrow mixed with HLA-haploidentical marrow transplantation in the treatment of patients with malignant blood disorders. In this report, 16 cases, including 12 with acute leukemia and four with advanced malignant lymphoma, were treated by autologous marrow, which was purged in vitro by hyperthemia following incubation for 5 days with IL-2 in liquid culture 8, 17 and mixed with HLA-haploidentical marrow cells from their sibling or parent. Acute GVHD was not observed in any patients, but, cGVHD was observed in eight patients who received the allogeneic marrow cells 2 h after ABMT. The major manifestations of cGVHD were skin lesions, diffuse hyperpigmentation, buccal mucositis, weight loss, chronic liver disorders, failure to thrive, and so on. However, it appeared about 1 month after MBMT and was different from that which occurred following allogeneic BMT, which always appeared 3 months after trans- was demonstrated in all cases but one, who died early from hepatic VOD. Mixed chimerism was found in three cases, with malignant blood diseases are reported. The results show that this mixed transplantation is, especially in recipiby analysis of sex chromosomes. Comparison of survival for patients who received allogeneic BMT 6 h after ABMT ents who received HLA-haploidentical marrow 2 h after ABMT, associated with a lower incidence of acute GVHD, with those 2 h after ABMT revealed that in the former group, five of eight patients relapsed with a median of 4 fewer complications, engraftment with partial mixed chimerism and a low relapse rate. Therefore, it is a safe, effecmonths, and died within 5 to 14 months. Two died from HVOD and encephalopathy at 3 weeks and 7 months, tive and new approach to treat patients with malignancies. In order to detect the effects of GVL, prospective studies respectively and only one patient is still DFS for more than 40 months. However, in the latter group, none relapsed with will be performed to confirm these findings. median follow-up of 12 months, all patients but two, who died from fulminant hepatatis and appendicular perforation
